These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12183594)

  • 1. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.
    Nwuba RI; Sodeinde O; Anumudu CI; Omosun YO; Odaibo AB; Holder AA; Nwagwu M
    Infect Immun; 2002 Sep; 70(9):5328-31. PubMed ID: 12183594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.
    Okafor CM; Anumudu CI; Omosun YO; Uthaipibull C; Ayede I; Awobode HO; Odaibo AB; Langhorne J; Holder AA; Nwuba RI; Troye-Blomberg M
    Malar J; 2009 Nov; 8():263. PubMed ID: 19930613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.
    Guevara Patiño JA; Holder AA; McBride JS; Blackman MJ
    J Exp Med; 1997 Nov; 186(10):1689-99. PubMed ID: 9362529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response dynamics to the Plasmodium falciparum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission.
    Torres KJ; Clark EH; Hernandez JN; Soto-Cornejo KE; Gamboa D; Branch OH
    Malar J; 2008 Sep; 7():173. PubMed ID: 18782451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.
    Morgan WD; Lock MJ; Frenkiel TA; Grainger M; Holder AA
    Mol Biochem Parasitol; 2004 Nov; 138(1):29-36. PubMed ID: 15500913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
    Singh S; Kennedy MC; Long CA; Saul AJ; Miller LH; Stowers AW
    Infect Immun; 2003 Dec; 71(12):6766-74. PubMed ID: 14638762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections.
    Murhandarwati EE; Black CG; Wang L; Weisman S; Koning-Ward TF; Baird JK; Tjitra E; Richie TL; Crabb BS; Coppel RL
    J Infect Dis; 2008 Oct; 198(8):1212-8. PubMed ID: 18717639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
    Johnson AH; Leke RG; Mendell NR; Shon D; Suh YJ; Bomba-Nkolo D; Tchinda V; Kouontchou S; Thuita LW; van der Wel AM; Thomas A; Stowers A; Saul A; Zhou A; Taylor DW; Quakyi IA
    Infect Immun; 2004 May; 72(5):2762-71. PubMed ID: 15102786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate.
    Pizarro JC; Chitarra V; Verger D; Holm I; Pêtres S; Dartevelle S; Nato F; Longacre S; Bentley GA
    J Mol Biol; 2003 May; 328(5):1091-103. PubMed ID: 12729744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
    Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.
    Murhandarwati EE; Wang L; Black CG; Nhan DH; Richie TL; Coppel RL
    Infect Immun; 2009 Oct; 77(10):4510-7. PubMed ID: 19620342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory.
    Clark EH; Silva CJ; Weiss GE; Li S; Padilla C; Crompton PD; Hernandez JN; Branch OH
    Infect Immun; 2012 Apr; 80(4):1583-92. PubMed ID: 22252876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria.
    Holder AA
    Parasitology; 2009 Oct; 136(12):1445-56. PubMed ID: 19627632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A and to the C terminus of merozoite surface protein 1 correlate with reduced placental malaria in Cameroonian women.
    Taylor DW; Zhou A; Marsillio LE; Thuita LW; Leke EB; Branch O; Gowda DC; Long C; Leke RF
    Infect Immun; 2004 Mar; 72(3):1603-7. PubMed ID: 14977967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodies.
    Omosun YO; Adoro S; Anumudu CI; Odaibo A; Holder AA; Nwagwu M; Nwuba RI
    Afr Health Sci; 2010 Jun; 10(2):106-10. PubMed ID: 21326959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.
    Uthaipibull C; Aufiero B; Syed SE; Hansen B; Guevara Patiño JA; Angov E; Ling IT; Fegeding K; Morgan WD; Ockenhouse C; Birdsall B; Feeney J; Lyon JA; Holder AA
    J Mol Biol; 2001 Apr; 307(5):1381-94. PubMed ID: 11292349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.
    Boyle MJ; Reiling L; Feng G; Langer C; Osier FH; Aspeling-Jones H; Cheng YS; Stubbs J; Tetteh KK; Conway DJ; McCarthy JS; Muller I; Marsh K; Anders RF; Beeson JG
    Immunity; 2015 Mar; 42(3):580-90. PubMed ID: 25786180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.